Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CND319 in Healthy Participants and Patients With Rheumatic Diseases
NCT07712939Phase 1Recruiting
- Sponsor
- Candid Therapeutics
- Start
- Jul 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of CND319 in rheumatoid arthritis (RA) and Sjögren's syndrome, sponsored by Candid Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 24 weeks, Changes to body temperature at 24 weeks and 8 more. Started Jul 2026; status: recruiting.
02
Drugs
CND319
03
Conditions
rheumatoid arthritis (RA)Sjögren's syndrome
Beyond the preview
Go deeper on NCT07712939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07712939.